News
Public · Published
Wells Fargo maintains CRISPR Therapeutics at Equal-Weight, lowers price target to $70 from $75
Wells Fargo kept its Equal-Weight rating on CRISPR Therapeutics but lowered its price target to $70 from $75, a 6.7% decrease. The revised target implies 40.0% upside from the November 3 closing price of $49.99.
Published:
Updated:
What happened
Wells Fargo kept its Equal-Weight rating on CRISPR Therapeutics but lowered its price target to $70 from $75, a 6.7% decrease. The revised target implies 40.0% upside from the November 3 closing price of $49.99.
Confirmed
Global impact / market context
The lower target signals that Wells Fargo sees less potential value than before, while keeping its rating unchanged. The target is an analyst estimate, not a guaranteed share price, and the article gives no explanation for the reduction or evidence of a change in the company’s business.
Analyst inference
The $70 target remains above the cited $49.99 closing price, so the analyst’s estimate still points to possible gains despite the cut. That gap reflects Wells Fargo’s view at the time, not a forecast shared by all analysts or a measure of future results.
Analyst inference
What to watch
- Look for any later Wells Fargo update to its rating or target; another revision could show whether the analyst’s view continues to change. Analyst inference
- Compare future CRISPR Therapeutics company updates with the reasons Wells Fargo gives, if any, for changing its target or rating. Analyst inference
- Watch whether the share price moves toward or away from the $70 target; the article does not report subsequent trading or investor reaction. Analyst inference
Evidence
- Original source link unavailable